- GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions
- GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025
- GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
- GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit
- GeoVax Labs Announces $2.5 Million Registered Direct Offering
- GeoVax Comments on U.S. “America First Global Health Strategy” and Highlights Company’s Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security
- GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications
- GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations
- GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference
- GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference
- GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference
- GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences
- GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs
- GeoVax to Present at the Emerging Growth Conference on August 20, 2025
- GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
- GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
- GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
- GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
- GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
- GeoVax to Advance Gedeptin(R) into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results
- GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025
- GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
- GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
- GeoVax to Present at the Emerging Growth Conference on July 16, 2025
- GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
- GeoVax Responds to Growing Mpox Threat with Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives
- GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering
- GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
- GeoVax Comments on FDA Approval of Keytruda® in Head and Neck Cancer, Underscoring Potential for Gedeptin® Combination Therapy
- GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
- GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA
- GeoVax to Participate in BIO International Convention 2025
- GeoVax Responds to WHO’s Fourth Declaration of Mpox as a Global Public Health Emergency
- GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
- GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
- GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology
- GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
- GeoVax Commends FDA’s Shift to Risk-Based COVID-19 Vaccination Guidance
- GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
- GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
- GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
- GeoVax Expands Gedeptin(R) Patent Portfolio
- GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
- GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
- GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
- GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
- GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
- GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
- GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
